Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Use of Human Perivascular Stem Cells for Bone Regeneration

Use of Human Perivascular Stem Cells for Bone Regeneration

Published on: May 25, 2012

Bone regeneration in athymic calvarial defects with Accell DBM100.

A Amir Mhawi¹, Sean Alexander Fitzgerald Peel, Tommy Chi-On Fok

¹Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.

The Journal of Craniofacial Surgery

|June 1, 2007

Summary

Accell DBM100, a bone graft material with 100% demineralized bone matrix (DBM), effectively promotes bone regeneration in rat calvarial defects. It shows promise for clinical use in craniofacial bone repair.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bone formation in algae-derived and synthetic calcium phosphates with or without poloxamer.

The Journal of craniofacial surgery·2013

Same author

Interaction of doxorubicin with the subcellular structures of the sensitive and Bcl-xL-overexpressing MCF-7 cell line: confocal and low-energy-loss transmission electron microscopy.

Micron (Oxford, England : 1993)·2009

Same author

Low-energy-loss electron microscopy of doxorubicin in human breast cancer MCF-7 cells: localization by color.

Journal of structural biology·2006

See all related articles

Area of Science:

Orthopedic Surgery
Biomaterials Science
Regenerative Medicine

Background:

Demineralized bone matrix (DBM) bioimplants are clinically used for bone defect repair due to their osteoinductive properties.
Traditional DBM preparations often incorporate inert carriers, diluting DBM content and potentially impacting efficacy.
Accell DBM100 utilizes processed DBM as its own carrier, achieving 100% DBM content.

Purpose of the Study:

To evaluate the efficacy of Accell DBM100 in promoting bone defect healing.
To compare the bone regenerative capacity of Accell DBM100 with OP-1 putty and unfilled controls.

Main Methods:

Forty-two athymic male rats underwent bilateral 5 mm calvarial defect creation.
Defects were treated with Accell DBM100, OP-1 putty, or left unfilled (control).

More Related Videos

Rapid Isolation of BMPR-IB+ Adipose-Derived Stromal Cells for Use in a Calvarial Defect Healing Model

Rapid Isolation of BMPR-IB+ Adipose-Derived Stromal Cells for Use in a Calvarial Defect Healing Model

Published on: February 24, 2017

Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate

Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate

Published on: October 31, 2012

Related Experiment Videos

Last Updated: Jul 14, 2026

Use of Human Perivascular Stem Cells for Bone Regeneration

Use of Human Perivascular Stem Cells for Bone Regeneration

Published on: May 25, 2012

Rapid Isolation of BMPR-IB+ Adipose-Derived Stromal Cells for Use in a Calvarial Defect Healing Model

Rapid Isolation of BMPR-IB+ Adipose-Derived Stromal Cells for Use in a Calvarial Defect Healing Model

Published on: February 24, 2017

Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate

Repair of a Critical-sized Calvarial Defect Model Using Adipose-derived Stromal Cells Harvested from Lipoaspirate

Published on: October 31, 2012

Histomorphometric analysis was performed at 4 and 8 weeks post-operation to quantify bone regeneration.

Main Results:

Both Accell DBM100 and OP-1 significantly increased bone formation compared to unfilled defects at 4 and 8 weeks.
OP-1 resulted in significantly more total reparative tissue (bone + marrow) than Accell.
The increase in new bone volume was not statistically significant between Accell and OP-1 at either time point.

Conclusions:

Accell DBM100 demonstrates significant bone regenerative potential in a rat calvarial defect model.
The findings suggest Accell DBM100 is a viable option for clinical application in craniofacial bone defect repair.